TP53TG1 interacts with the oncogenic protein phosphatase 2A inhibitor (CIP2A), triggering its ubiquitination-mediated degradation and inhibiting the PI3K/AKT pathway, underscoring its antitumor significance in GC progression (Fang D. et al., 2022). This evidence concerns the gene PIK3CG and gastric cancer.